Cite
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
MLA
Bröckelmann, Paul J., et al. “Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.” Journal of Clinical Oncology, vol. 41, no. 6, Feb. 2023, pp. 1193–99. EBSCOhost, https://doi.org/10.1200/JCO.22.02355.
APA
Bröckelmann, P. J., Bühnen, I., Meissner, J., Trautmann-Grill, K., Herhaus, P., Halbsguth, T. V., Schaub, V., Kerkhoff, A., Mathas, S., Bormann, M., Dickhut, A., Kaul, H., Fuchs, M., Kobe, C., Baues, C., Borchmann, P., Engert, A., & von Tresckow, B. (2023). Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. Journal of Clinical Oncology, 41(6), 1193–1199. https://doi.org/10.1200/JCO.22.02355
Chicago
Bröckelmann, Paul J., Ina Bühnen, Julia Meissner, Karolin Trautmann-Grill, Peter Herhaus, Teresa V. Halbsguth, Valdete Schaub, et al. 2023. “Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.” Journal of Clinical Oncology 41 (6): 1193–99. doi:10.1200/JCO.22.02355.